Research programme: neurodegenerative disease therapeutics - Takeda/University College London
Latest Information Update: 19 Oct 2015
At a glance
- Originator Takeda; University College London
- Mechanism of Action Genetic process modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Neurodegenerative disorders
Most Recent Events
- 13 Oct 2015 Early research in Neurodegenerative disorders in United Kingdom (unspecified route)